3 results
Approved WMORecruiting
The primary objective of the study is to evaluate if treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition in first line followed at progression by fulvestrant in second line (strategy A) improves progression-free…
Approved WMOCompleted
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
Approved WMORecruiting
To analyze the molecular effects and dose-response relationship of HBOT in patients with moderate-to-severe UC refractory to medical therapy, more specifically to evaluate: - Clinical, endoscopic, histological and ultrasonographic disease activity-…